Journals / Journal of Microbiology and Infectious Diseases / 2012 / Cilt: 2 - Sayı: 02

Evaluation of immune status against hepatitis B in children with thalassemia major in Egypt: A single center study

Pages
44–49
Publication Date
2012-06-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

So, we recommend screening of thalassemic patients at age of 3 years to evaluate the need of a booster dose.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Thalassemic children with repeated blood transfusion are at higher risk of suffering transfusion related infections including hepatitis B virus (HBV).
📊
Key Findings & Data:HBV vaccine immunogenicity in several studies showed variable response rates.
💡
Conclusion & Impact:So, we recommend screening of thalassemic patients at age of 3 years to evaluate the need of a booster dose.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Thalassemia · HBV · vaccination

Abstract

Objectives: Thalassemic children with repeated blood transfusion are at higher risk of suffering transfusion related infections including hepatitis B virus (HBV). HBV vaccine immunogenicity in several studies showed variable response rates. The aim of this study is to evaluate the immunogenic effect of hepatitis B vaccine in thalassemic children at different age groups. Materials and methods: After ethical approval and informed parent consent, 125 diagnosed thalassemic patients were recruited from the Hematology/Oncology Unit, Pediatric Department, Tanta University Hospital. Patient&#39;s transfusion, and vaccination history, clinical data, and blood samples were obtained. Patient&#39;s sera were stored at -20&deg;C till tested for Anti-hepatitis B surface (anti-HBs) by ELISA. Patients with titers <10 IU were tested for HBs-Ag. Results: Although none of our cases had hepatitis B virus infection, only 20.8% had a protective anti-HBs titer (>10 IU/L). Significantly higher percentage of protected patients (40.1%) were younger than 3 years of age, while age groups above 3years showed a significant trend towards having non protective titers (p=0.003). Anti-HBs titers weren&#39;t correlated to age, ferritin, liver enzymes, and duration of transfusion or number of transfused packs. Conclusion: Protective Anti-HBs titer was reduced after age of 3 years in our patients. So, we recommend screening of thalassemic patients at age of 3 years to evaluate the need of a booster dose.

🔖

Cite This Article

Soliman, H. H., A., I. K., El-Shanshory, M. R., Nagy, H. M., Abdou, S. H. (2012). Evaluation of immune status against hepatitis B in children with thalassemia major in Egypt: A single center study. Journal of Microbiology and Infectious Diseases, Cilt: 2 - Sayı: 02, 44–49. https://ajindex.com/articles/48336

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Sexana A, Phadke SR. Feasibility of thalassemia control by extended family screening in Indian context. J Health Popul Nutr 2002; 20:31-35.
  2. El-Beshlawy A, Kaddah N, Moustafa A, et al. Screening for ß-thalassemia carriers in Egypt: Significance of the osmotic fragility test. East Mediterr Health J 2007; 13:224-230.
  3. Rund D, Rachmilewitz E. ß-Thalassemia. N Engl J Med 2005; 353:1135-1146.
  4. Bassily S, Hyams K, Fouad R, Samfaan M, and Hibbs R. A high risk of hepatitis C infection among Egyptian blood do- nors: The role of parenteral drug abuse. Am J Trop Med Hyg 52; 1995: 503-505.
  5. Hauri A, Armstrong G, Hutin Y. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 7-16.
  6. Davis AR, Rosenthal P. Hepatitis B in children. Pediatr Rev 2008; 29:111-120
  7. Elisofon SA, Jonas MM. Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis 2006; 10:133- 148. El-Gilany AH, El-Fedawy S. Bloodborne infections among stu- dent voluntary blood donors in Mansoura University, Egypt. East Mediterr Health J 2006; 12:742-748. Kao JH; Chen DS. Global control of hepatitis B virus infection, Lancet Infect Dis 2002; 2:395-403. Kirk GD. Hepatitis B vaccination and liver cancer. In: Stew- art BW, Kleihues P (Eds).World Cancer Report. Lyon: IARC Press, 2003, 144-147.
  8. Bonanni P, Pesavento G, Bechini A, et al. Impact of universal vaccination programs on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine 2003; 21: 685-691.
  9. Fitzsimons D, François G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B mutants. Vaccine 2005; 23:4158-4166. World Health Organization. Last update: 3 October 2011,
  10. Immunization Profile-Egypt, WHO Vaccine Preventable Dis- eases Monitoring System web site, http://apps.who.int/im- munization_monitoring/en/globalsummary/countryprofilere- sult.cfm?C=egy [accessed Oct 5, 2011]
  11. Rivkina A, Pharm D, Rybalov S. Chronic hepatitis B: Cur- rent and future treatment options. Pharmacotherapy 2002; 22: 721-737.
  12. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twen- ty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. Vaccine 2008; 2; 26:6587-6591.
  13. Saberifiroozi M, Gholamzadeh S, Serati AR. The long-term immunity among health care workers vaccinated against hepatitis B virus in a large referral hospital in southern Iran. Arch Iran Med.2006; 9:20